ImetelChat

So IMbark has 76 locations now of which recruiting: Duarte, California, United States La Jolla, California, United States Louisville, Kentucky, United States Baltimore, Maryland, United States Rochester, Minnesota, United States St. Louis, Missouri, United States Bronx, New York, United States New Y...

Hi Bio, as I said, comments and improvements are appreciated. So let's start making this list more precise. What are your other observations?

I revisited an earlier overview from YMB of Geron's state of play since 2nd part of 2014. I am reposting it here, including some new facts. (version 5, updated 15 July 2016) on imetelstat: 1. partial clinical hold lifted; 2. 3 x ODD status: for MF in the US and EU, for MDS in the US 4. JnJ deal with...

Maybe a first atempt to set up a timeline based on events/milestones: Clinical: Imbark & Imerge: early readouts CT1951: Estimated Primary Completion Date: March 2017 (Final data collection date for primary outcome measure); Can we expect other milestones from this study? AML: start clinical combi-tr...

btw: irish is here, as well as known experts such as Phil, Greg BioPearl and Hoosier. Good ingredients to start a good discussion, I would say....

Hi idomer, welcome here! Good suggestion: any form serious discussion is highly appreciated. Speculating about timelines is especially interesting, because for that we need to try to see the unkowns based on what we do know. So let's start the discussion and see how much we can get to the table! The...

It already has been said at other occasions: ET is not so 'innocent' as we may think. This article suggests that there are significantly more PreMF cases amongst ET diagnosed patients than we currently acknowledge. That means that imetelstat may very well play a life saving role for a significant su...

(from September 2015; I didn't see it before) Women and MPN Conference, San Diego 11-12 September 2015 Genetics and Targeted Therapy of MPN, by Dr. Raajit Rampal MD At 23:55 of the video he speaks about imetelsat, its mechanism and the promising results as reported by Tefferi, Baerlocher and NEJM. l...

I see...Tx

Jakafi's solid tumor program goes belly up. by George Budwell What: Shares of Incyte Corporation (NASDAQ:INCY) fell by more than 21% in early morning trading today after the company announced that it is discontinuing the clinical development of Jakafi (ruxolitinib) in solid tumors due to insufficien...

Wow, you are right, Bio. I missed that second press release. Doesn't look good for pacritinib....

Link: http://www.prnewswire.com/news-releases ... 17839.html

(btw: who is Kemosabe?)

Bio, the Citi press release says it's a partial hold. SEATTLE, Feb. 8, 2016 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA:CTIC) today announced that the Company received written communication from the U.S. Food and Drug Administration (FDA) on February 4, 2016, that the FDA has...

repost from sdrawkcabeman (YMB) Everyone's familiar w/Rux's profile which, broadly, is very modest efficacy w/myelosuppression, abnormal LFTs, and up to 89% discontinuation w/in 3 yrs. SNY's Fedratinib was scrapped b/c pts developed Wernicke's encephalopathy. The whole program was written off, this ...

Hi Bio, I will get into it later today, as I am a bit busy right now. Btw: changes on the CT site are not just administrative matters. Changing texts have a good wellthough off reasoning behind. Let's see if we can get a grasp of the wider meaning of these changes.

This is about pacritnib?

Bio, you raise a very interesting point. I will take a closer at this later, as I am a bit in a hurry. For now I see three significant changes: - duration from 3 to 5 years - the definition of the study-end is changed - they skipped the wordings 'unacceptable toxicity' and changed it into 'as long a...

This is the link to the abstract: http://online.liebertpub.com/doi/abs/10 ... .2015.0558

(I couldn't find a link to the PDF you mentioned)

Phil Pecsok from Seeking Alpha said the following about this tool when applied to imetelstat: ====== This is THE algo that JANSSEN considered when it partnered with Geron. Go to page 4. Note scores are 0-1-2 for each of 4 questions. #1. IMET has 40% activity if you look at CR/PR/CI and higher if you...

Authors: Tufts Center for the Study of Drug Development and Janssen Research & Development R&D Senior Leadership Brief (excerpt of the summary) Starting in 2012, the Tufts Center for the Study of Drug Development (Tufts CSDD) and Janssen Research & Development (JRD) collaborated on a pilot study to ...

Yes, it is a competing drug. So maybe good news for Geron. But for patients it is bad news, because it performed better than Jakafi.... With the requested changes to the protocol the FDA wants to get a better insight in the mortality cases, partly by not allowing patients crossing over to the other ...